Literature DB >> 23097187

Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.

Yuki Kagiyama1, Jiro Kitaura, Katsuhiro Togami, Tomoyuki Uchida, Daichi Inoue, Toshihiro Matsukawa, Kumi Izawa, Kimihito C Kawabata, Yukiko Komeno, Toshihiko Oki, Fumio Nakahara, Katsuaki Sato, Hiroyuki Aburatani, Toshio Kitamura.   

Abstract

Activating mutations of c-Kit are frequently found in acute myeloid leukemia (AML) patients harboring t(8;21) chromosomal translocation generating a fusion protein AML1-ETO. Here we show that an active mutant of c-Kit cooperates with AML1-ETO to induce AML in mouse bone marrow transplantation models. Leukemic cells expressing AML1-ETO with c-Kit(D814V) were serially transplantable. Transplantation experiments indicated that lineage(-)c-Kit(+)Sca-1(+) (KSL) leukemic cells, but not lineage(+) leukemic cells, were enriched for leukemia stem cells (LSCs). Comparison of gene expression profiles between KSL leukemic and normal cells delineated that CD200R1 was highly expressed in KSL leukemic cells as compared with KSL normal cells. Upregulation of CD200R1 was verified in lineage(-) leukemic cells, but not in lineage(+) leukemic cells. CD200R1 expression in the lineage(-) leukemic cells was not correlated with the frequency of LSCs, indicating that CD200R1 is not a useful marker for LSCs in these models. Interestingly, CD200R1 was upregulated in KSL cells transduced with AML1-ETO, but not with other leukemogenic mutants, including c-Kit(D814V), AML1(D171N), and AML1(S291fsX300). Consistently, upregulation of CD200R1 in lineage(-) leukemic cells was observed only in the BM of mice suffering from AML1-ETO-positive leukemia. In conclusion, AML1-ETO upregulated CD200R1 in lineage(-) cells, which was characteristic of AML1-ETO-positive leukemia in mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23097187     DOI: 10.1007/s12185-012-1207-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  39 in total

1.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Authors:  Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

2.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.

Authors:  K L Rhoades; C J Hetherington; N Harakawa; D A Yergeau; L Zhou; L Q Liu; M T Little; D G Tenen; D E Zhang
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

3.  TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

Authors:  Yoshikane Kikushige; Takahiro Shima; Shin-ichiro Takayanagi; Shingo Urata; Toshihiro Miyamoto; Hiromi Iwasaki; Katsuto Takenaka; Takanori Teshima; Toshiyuki Tanaka; Yoshimasa Inagaki; Koichi Akashi
Journal:  Cell Stem Cell       Date:  2010-12-03       Impact factor: 24.633

Review 4.  Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.

Authors:  Susumu Goyama; James C Mulloy
Journal:  Int J Hematol       Date:  2011-05-03       Impact factor: 2.490

5.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

Authors:  Brian J P Huntly; Hirokazu Shigematsu; Kenji Deguchi; Benjamin H Lee; Shinichi Mizuno; Nicky Duclos; Rebecca Rowan; Sonia Amaral; David Curley; Ifor R Williams; Koichi Akashi; D Gary Gilliland
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

6.  CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

Authors:  Naoki Hosen; Christopher Y Park; Naoya Tatsumi; Yusuke Oji; Haruo Sugiyama; Martin Gramatzki; Alan M Krensky; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

7.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

Authors:  J Wang; T Hoshino; R L Redner; S Kajigaya; J M Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.

Authors:  Gavin J Wright; Holly Cherwinski; Mildred Foster-Cuevas; Gary Brooke; Michael J Puklavec; Mike Bigler; Yaoli Song; Maria Jenmalm; Dan Gorman; Terri McClanahan; Man-Ru Liu; Marion H Brown; Jonathon D Sedgwick; Joseph H Phillips; A Neil Barclay
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

9.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

10.  Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

Authors:  V Gelmetti; J Zhang; M Fanelli; S Minucci; P G Pelicci; M A Lazar
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  3 in total

1.  Evaluation of a Small Animal Irradiation System for Animal Experiments Using EBT3 Model GAFCHROMIC™ Film.

Authors:  Yasuyuki Shimizu; Hiroaki Akasaka; Daisuke Miyawaki; Naritoshi Mukumoto; Masao Nakayama; Tianyuan Wang; Saki Osuga; Sachiko Inubushi; Ryuichi Yada; Yasuo Ejima; Kenji Yoshida; Takeaki Ishihara; Ryohei Sasaki
Journal:  Kobe J Med Sci       Date:  2018-01-17

2.  A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0-G1 transition.

Authors:  Toshihiko Oki; Koutarou Nishimura; Jiro Kitaura; Katsuhiro Togami; Akie Maehara; Kumi Izawa; Asako Sakaue-Sawano; Atsushi Niida; Satoru Miyano; Hiroyuki Aburatani; Hiroshi Kiyonari; Atsushi Miyawaki; Toshio Kitamura
Journal:  Sci Rep       Date:  2014-02-06       Impact factor: 4.379

Review 3.  The molecular basis of myeloid malignancies.

Authors:  Toshio Kitamura; Daichi Inoue; Naoko Okochi-Watanabe; Naoko Kato; Yukiko Komeno; Yang Lu; Yutaka Enomoto; Noriko Doki; Tomoyuki Uchida; Yuki Kagiyama; Katsuhiro Togami; Kimihito C Kawabata; Reina Nagase; Sayuri Horikawa; Yasutaka Hayashi; Makoto Saika; Tomofusa Fukuyama; Kumi Izawa; Toshihiko Oki; Fumio Nakahara; Jiro Kitaura
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2014       Impact factor: 3.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.